Phase 2 Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- The person joining (or their legal representative) must sign a consent form showing they understand the study and agree to take part, before any study procedures begin.
- Adults aged 18 to 60 years old at the time of screening (or the legal adult age in their country, whichever is higher).
- People who have been newly diagnosed with a specific type of blood cancer called acute myeloid leukemia (AML) that has a particular gene change called FLT3-ITD, classified as intermediate risk under a standard medical guideline called ELN 2022.
- People whose general health and organ function (including liver, kidneys, and heart) are within acceptable ranges, as measured by blood tests and a heart scan within a set timeframe before joining.
Who may not be able to join:
- People diagnosed with certain specific types of AML, including a type called acute promyelocytic leukemia (APL), a type linked to a gene change called BCR-ABL, or AML that developed as a result of previous chemotherapy or radiation treatment.
- People with a history of another cancer, unless it was a non-serious skin condition, a fully cured early-stage cancer, or a solid tumour that was treated and has shown no signs of returning for at least 2 years.
- People whose overall health or organ function means they are considered unsuitable for intensive chemotherapy, based on factors such as heart problems, lung problems, kidney problems, liver problems, or other serious health conditions.
- People with an active infection (fungal, bacterial, or viral) that is not under control.
- People with a known active liver disease such as active hepatitis B or C, or a known history of HIV infection.
- People with a known allergy to any ingredient in the study medication (gilteritinib tablets).
- People who are pregnant or breastfeeding.
- People the trial doctor considers unsuitable for any other reason.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +8613867439726
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Composite Complete Remission (CRc) Rate after 2 induction cycles
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.